# Evorpacept (ALX148) in Combination With Pembrolizumab in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-03)

> **NCT04675294** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **ALX Oncology Inc.** · enrollment: 189 (actual)

## Conditions studied

- Head and Neck Cancer
- Head and Neck Squamous Cell Carcinoma

## Interventions

- **DRUG:** evorpacept
- **DRUG:** pembrolizumab

## Key facts

- **NCT ID:** NCT04675294
- **Lead sponsor:** ALX Oncology Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-04-02
- **Primary completion:** 2025-03-03
- **Final completion:** 2026-06-30
- **Target enrollment:** 189 (ACTUAL)
- **Last updated:** 2025-08-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04675294

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04675294, "Evorpacept (ALX148) in Combination With Pembrolizumab in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-03)". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT04675294. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*